Traphagen Investment Advisors LLC Buys Shares of 30,500 CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Traphagen Investment Advisors LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 30,500 shares of the biotechnology company’s stock, valued at approximately $31,000.

Several other hedge funds also recently made changes to their positions in CTMX. US Bancorp DE purchased a new stake in CytomX Therapeutics during the 3rd quarter worth about $40,000. XTX Topco Ltd boosted its position in shares of CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 48,033 shares during the period. Forefront Analytics LLC increased its holdings in CytomX Therapeutics by 206.7% during the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 43,176 shares during the period. Cubist Systematic Strategies LLC lifted its stake in CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of CytomX Therapeutics during the 3rd quarter valued at $104,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, CytomX Therapeutics has an average rating of “Hold” and a consensus target price of $5.77.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $0.87 on Wednesday. The company has a market capitalization of $68.18 million, a P/E ratio of 5.12 and a beta of 1.03. CytomX Therapeutics, Inc. has a 52-week low of $0.79 and a 52-week high of $5.85. The company has a fifty day moving average of $1.03 and a 200-day moving average of $1.15.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. The firm had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the prior year, the business earned $0.04 EPS. As a group, analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.